Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial

Li, Yan; Ma, Hongli; Zhang, Yuehui; Kuang, Hongying; Ng, Ernest Hung Yu; Hou, Lihui; Wu, Xiaoke

doi:10.1186/1745-6215-14-226

Cited by 31 publications

(24 citation statements)

References 20 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insulin resistance is significantly associated with the long‐term risks of metabolic syndrome and cardiovascular disease. Berberine reduces insulin resistance similar to metformin (Li et al ., ). Some studies have evaluated the effect of berberine on insulin resistance in women with PCOS (Wei et al ., ; Li et al ., ; Li et al ., ).…”

Section: Endocrine Effectsmentioning

confidence: 99%

Berberis Vulgaris and Berberine: An Update Review

Imenshahidi

Hosseinzadeh

2016

Phytotherapy Research

264

180

View full text Add to dashboard Cite

Berberine is an isoquinoline alkaloid present in several plants, including Coptis sp. and Berberis sp. Berberine is a customary component in Chinese medicine, and is characterized by a diversity of pharmacological effects. An extensive search in electronic databases (PubMed, Scopus, Ovid, Wiley, ProQuest, ISI, and Science Direct) were used to identify the pharmacological and clinical studies on Berberis vulgaris and berberine, during 2008 to 2015, using 'berberine' and 'Berberis vulgaris' as search words. We found more than 1200 new article studying the properties and clinical uses of berberine and B. vulgaris, for treating tumor, diabetes, cardiovascular disease, hyperlipidemia, inflammation, bacterial and viral infections, cerebral ischemia trauma, mental disease, Alzheimer disease, osteoporosis, and so on. In this article, we have updated the pharmacological effects of B. vulgaris and its active constituent, berberine. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Section: Endocrine Effectsmentioning

confidence: 99%

Berberis Vulgaris and Berberine: An Update Review

Imenshahidi

Hosseinzadeh

2016

Phytotherapy Research

264

180

View full text Add to dashboard Cite

show abstract

“…Polycystic ovarian syndrome (PCOS) is a prevalent endocrine condition with important endocrine, cardiovascular, and metabolic consequences (Rooney & Pendry, ). Hyperinsulinemia and insulin resistance have a key role in the pathogenesis of PCOS that is characterized by ovulatory dysfunction, hyperandrogenism, and presence of polycystic ovaries (Li et al, ).…”

Section: Endocrinementioning

confidence: 99%

Berberine and barberry (Berberis vulgaris): A clinical review

Imenshahidi

Hosseinzadeh

2019

Phytotherapy Research

254

134

View full text Add to dashboard Cite

Barberry (Berberis vulgaris L.) has different medicinal applications in folk medicine of Iran. Berberine, an alkaloid constituent of this plant, is present in the roots, rhizomes, stem, and bark of B. vulgaris and many other plants. There have been many clinical trials conducted that suggested a wide range of therapeutic applications. Here, we investigated the clinical uses of berberine and B. vulgaris in the treatment of different diseases in humans. An extensive search in electronic databases (PubMed, Scopus, Embase, Web of Sciences and Science Direct) was used to identify the clinical trials on B. vulgaris and berberine. Lipid‐lowering and insulin‐resistance improving actions are the most studied properties of berberine in numerous randomized clinical trials. There are also clinical trials regarding cardiovascular, anticancer, gastrointestinal, CNS, endocrine, and so on. Berberine has very low toxicity in usual doses and reveals clinical benefits without major side effects. Only mild gastrointestinal reactions may occur in some patients. The purpose of this review is to provide a summary concerning the clinical trials conducted on berberine to improve the clinical application of this nutraceutical in different diseases. In this review article, we used 77 clinical studies on human subjects.

show abstract

“…One potential prophylactic candidate, berberine (BBR), merits further exploration as it has already proved to be of importance for a variety of diseases through successful clinical trials, such as polycystic ovary syndrome [30,31], type II diabetes [32,33], diarrhea-predominant irritable bowel syndrome [34], psoriasis [35], and osteoarthritis [36]. Additionally, current clinical trials are assessing BBR's ability to help ulcerative colitis (UC) patients maintain remission (NCT No.02962245), to prevent colorectal cancer development in UC patients who are in remission (NCT No.…”

Section: Berberinementioning

confidence: 99%

Berberine delays onset of collagen induced arthritis through T cell suppression

Vita¹,

Lyons²,

Aljobaily³

et al. 2019

Preprint

View full text Add to dashboard Cite

RUNNING TITLE (less than 50 characters): Berberine delays onset of collagen arthritis model KEY WORDS (5 words not in the title): CIA, berberine, RA, autoimmune, T cell ABSTRACT (250 words or less): Previous evidence suggests that berberine (BBR), a clinically relevant plant-derived alkaloid, alleviates symptoms of clinically apparent collagen induced arthritis (CIA), and may have a prophylactic role from in vitro studies. Thus, we used a CIA model to determine if BBR merits further exploration as a prophylactic treatment for rheumatoid arthritis. Mice were treated with either 1 mg/kg/day of BBR or a vehicle (PBS) control via IP injections from day 0 to day 28, were left untreated (CIA control), or were in a non-arthritic control group. Incidence of arthritis in BBR mice was 40%, compared to 90% in the CIA and 80% in the PBS controls. Populations of B cells and T cells from the spleens and draining lymph nodes were examined from mice across treatment groups on day 14 and from the remaining mice on day 28 when arthritic signs and symptoms were expected to be apparent. BBR-treated mice had significantly reduced populations of CD4 + T cells, CXCR5 + T fh cells, and an increased proportion of T reg at both day 14 and day 28 endpoints, as well as decreased CD28 + and CD154 + CD4 + T cells at day 14. BBR-treated mice also experienced a significant reduction of CD19 + B cells in LNs at day 28. Additionally, BBR treatment resulted in significantly lower anti-collagen type II-specific (anti-CII) IgG2a and anti-CII total IgG serum concentrations. These results indicate a potential role for BBR as a prophylactic supplement, and that its effect may be mediated through T cell suppression, which indirectly affects B cell activity. and PBS controls ( Fig. 2B). When comparing anti-CII IgG levels between arthritic and nonarthritic mice within the BBR group specifically, however, anti-CI IgG1, IgG2a and total IgG were all significantly reduced in the non-arthritic mice compared to those who developed arthritis (Fig. 2C). Additionally, there appeared to be a vehicle-specific effect on circulating anti-CII IgG in which the administration of PBS with 0.01% DMSO elicited elevated levels of anti-CII IgG1 and total IgG in vehicle control mice ( Fig. 2A-B).Key CD4 + T cell population characteristics in response to berberine treatment-On day 14, we observed a significant reduction in populations of both CD4 + T cells and CXCR5 + T fh cells in the LNs and spleen of BBR-treated mice (Fig. 3A-B), as well as a reduction in the percentage of CD28 + and CD154 + CD4 + T cells in the spleen and LNs of BBR-treated mice (Fig. 3A-B). By the day 28 experimental endpoint we continued to observe a significant reduction in CD4 + T cells and CXCR5 + T fh cells in the spleen and LNs of BBR-treated mice ( Fig. 3C-D), however, there was no significant difference in the percentage of CD28 + and CD154 + CD4 + T cells between treatment groups (Fig 3C-D). Berberine treatment leads to increased proportion of FOXP3 + CD25 + CD4 + T cells-To examineBBRs effect on ...

show abstract

Effect of berberine on insulin resistance in women with polycystic ovary syndrome: study protocol for a randomized multicenter controlled trial

Cited by 31 publications

References 20 publications

Berberis Vulgaris and Berberine: An Update Review

Berberis Vulgaris and Berberine: An Update Review

Berberine and barberry (Berberis vulgaris): A clinical review

Berberine delays onset of collagen induced arthritis through T cell suppression

Contact Info

Product

Resources

About